Compare Citius Pharmaceuticals Inc (CTXR) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs VanEck Semiconductor ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while VanEck Semiconductor ETF trades at $585.47. The key difference: VanEck Semiconductor ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SMH | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | — |
52-Week High | $1.82 | $668.91 |
52-Week Low | $0.48 | $286.43 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
SMH trades at $588.23, up 3.31% today, with a neutral technical signal and mixed momentum indicators. The ETF faces headwinds from semiconductor sector volatility and recent downgrades, while institutional interest remains active with new stakes from firms like Ferguson Shapiro LLC. Support and resistance levels suggest consolidation near current prices, with key levels at $560 support and $587 resistance.
Outlook is cautious due to sector rotation and AI-driven volatility, though long-term demand for semiconductors remains strong. Risks include tariff impacts and competitive ETF performance, but strategic positioning in AI and memory markets offers growth potential for patient investors amid near-term uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
